Johnson & Johnson’s upcoming Q3 2026 earnings, scheduled for October 13, reflect a 75.5% market-implied probability of beating consensus amid solid underlying operational momentum. Pharma segment growth, fueled by oncology assets like Darzalex, Carvykti, and Tecvayli plus immunology launches such as Tremfya and Icotyde, supports expected revenue of roughly $25.3 billion, up about 5–6% year-over-year. Recent quarters show consistent beats on sales and adjusted EPS, with full-year guidance raised earlier in 2026 to $101.1 billion in sales and $11.68 adjusted EPS. Offsetting factors include the anticipated $0.64 per share in-process R&D dilution from acquisitions and partnerships, which some analysts project could push reported EPS below the $2.77–$2.90 street range. Traders are pricing the likelihood that core business strength outweighs these one-time items, with limited estimate revisions ahead of the print.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日View resolved

外部リンクに注意してください。
外部リンクに注意してください。
よくある質問